<p>Mauna Kea Technologies SA hat die Ernennung von Benoit Chardon zum Fractional Chief Commercial Officer bekannt gegeben. Chardon übernimmt die globale Skalierung der CellTolerance®-Plattform außerhalb der USA, um das internationale Wachstum des Unternehmens insbesondere in Europa, dem Nahen Osten und Australien zu beschleunigen. Die organisatorischen Änderungen folgen auf ein starkes Jahr 2025 mit Rekordumsätzen im Bereich Bauchspeicheldrüsenzysten und der erfolgreichen Einführung von CellTolerance®. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mauna Kea Technologies SA published the original content used to generate this news brief on February 04, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here</p>

<p>Mauna Kea Technologies SA has appointed Benoit Chardon as the Fractional Chief Commercial Officer. Chardon will oversee the global scaling of the CellTolerance® platform outside the USA, aiming to accelerate the company's international growth, particularly in Europe, the Middle East, and Australia. This organizational change follows a strong 2025 with record revenues in pancreatic cysts and the successful launch of CellTolerance®.</p>

Reuters

Guotai CSI Bio-medicine ETF

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

First Trust NYSE Arca Biotech Index Fd

Health Care Select Sector SPDR

Ark Genomic Revolution ETF

China Merchants CSI Biotechnology Theme ETF

BlackRock, Inc.

iShares Global Healthcare

E Fund CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

VanEck Biotech ETF

Minsheng Royal CSI Biotechnology Theme ETF

ALPS Medical Breakthrough

Bosera Hang Seng SCHK Innovative Drug Select ETF

Bosera Hang Seng Health Care ETF(QDII)

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

VG Health

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

SPDR S&P Health Equip

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

iShares US Medical Devices

Proshares UltraShort Nasdaq Biotech

China Merchants CSI All Share Medical Apparatus and Instruments ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Mauna Kea Technologies ernennt Benoit Chardon zum Chief Commercial Officer für CellTolerance